OGX might run. Crap raise, placement oversubscribed - duh, but discovery looks to be the real deal. If not, the Co has given me enough detail to hang them.
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%
